

Mail Stop 6010

May 2, 2007

Benjamin F. McGraw, III, Pharm.D.
President, Chief Executive Officer and Treasurer
Valentis, Inc.
863A Mitten Rd.
Burlingame, California 94010

Re: Valentis, Inc.
Amendment No. 2 to Registration Statement on Form S-4
File No. 333-140443
Filed April 24, 2007

Dear Dr. McGraw:

We have reviewed your filing and have the following comments. Where indicated, we think you should revise your document in response to these comments. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. Please be as detailed as necessary in your explanation. In some of our comments, we may ask you to provide us with supplemental information so we may better understand your disclosure. After reviewing this information, we may or may not raise additional comments.

Please understand that the purpose of our review process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or on any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter.

General

1. We note your response to our prior comment 2. We are not in receipt of Exhibits A and B that accompanying the affidavit attached to your application pursuant to Rule 437 to dispense with the filing of the consent. Please provide us those exhibits. We may have further comments once we have received the exhibits.

Urigen's agreements with vendors and a business partner, page 45

2. We note your response to our prior comment 7 and reissue the comment. Please revise the risk factor to estimate the number of shares of Series B preferred stock that Urigen may be required to issue and how this may affect the number of shares Valentis is required to issue to Urigen stockholders in the merger or after the merger. In particular, please provide an estimate of the number of shares that may be issuable for the milestone fees.

Urigen's Reasons for the Merger, page 62

3. We note your response to our prior comment 11 and reissue that comment. Please disclose the appropriate information required by Item 1015 of Regulation M-A regarding this valuation analysis performed by Bio-IB, LLC. The disclosure should summarize the analysis, including the conclusion regarding the fair value of the relevant intangible assets. Please also include the analysis as an exhibit to the registration statement.

Unaudited Pro Forma Combined Condensed Consolidated Financial Statements, page 130

4. We have read your response to comment 15 and your revised disclosures. Please revise your disclosures to clarify that the purchase price was determined by the fair value of the net assets acquired. Please clarify the accounting for the purchase, including the fact that no goodwill was recorded.

Urigen Holdings Financial Statements, page F-34

5. We have read your response to comment 24 and your revised disclosures. However, the June 30, 2006 audited financial statements have not been updated to reflect the two for one stock split in October 2006. Please revise the June 30, 2006 financial statements to retroactively apply the effects of this stock split. Please include a note to the financial statements to clearly indicate that this is the accounting treatment applied to this stock split. In addition, it appears as though the amount of common stock issued at December 31, 2006 disclosed on the balance sheet should be 15,506,490 rather than 31,012,980, please explain.

* * * * *

As appropriate, please amend your filing in response to these comments. You may wish to provide us with marked copies of the amendment to expedite our review.

Benjamin F. McGraw, III, Pharm.D.
Valentis, Inc.
May 2, 2007
Page 3

Please furnish a cover letter with your amendment that keys your responses to our comments and provides any requested supplemental information. Detailed cover letters greatly facilitate our review. Please file your cover letter on EDGAR under the form type label CORRESP. Please understand that we may have additional comments after reviewing your amendment and responses to our comments.

We direct your attention to Rules 460 and 461 regarding requesting acceleration of a registration statement. Please allow adequate time after the filing of any amendment for further review before submitting a request for acceleration. Please provide this request at least two business days in advance of the requested effective date.

You may contact Vanessa Robertson at (202) 551-3649 or Lisa Vanjoske at (202) 551-3614 if you have questions regarding comments on the financial statements and related matters. Please contact Sonia Barros at (202) 551-3655 or me at (202) 551-3715 with any other questions.

Sincerely,

Jeffrey P. Riedler
Assistant Director

cc: Robert C. Funsten, Esq.
Marc G. Alcser, Esq.
Michael L. Lawhead, Esq.
Stradling Yocca Carlson & Rauth
660 Newport Center Drive, Suite 1600
Newport Beach, California 92660